Pharmacy Rotations
Click here to read testimonies from our employees who enrolled in our pharmacy rotations academic program.
Search
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status
Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
History
History
Cyltezo® (adalimumab-adbm): First Interchangeable Biosimilar | BI US
Read more about how the FDA have approved CYLTEZO as the first interchangeable biosimilar with Humira®, supported by data from BI’s Phase III clinical trial.
Our Partners: ViraTherapeutics
Our Partners: ViraTherapeutics
Fornovo San Giovanni (Bidachem)
Founded in 1981, Fornovo San Giovanni serves both – Human Pharma and Animal Health
Rewards and recognition
There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
Lyon
The Lyon region is a key global hub for the Animal Health business of the company, encompassing research, development, production and supply of veterinary products.
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio
US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction
Purpose Video IT
Agustina Rojo, System Analyst in Buenos Aires, Argentina explains the many career opportunities Boehringer Ingelheim provides its employees.
Immunology
Immunology
BI Beyond Borders: Science, Collaboration, Geography | BI US
Read more on how the Company’s ‘radar’ for the next big wave of innovation, the RBB team, is tasked with exploring emerging science and technologies.
Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US
Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.
The Importance of Drug Discovery | R&D | Boehringer Ingelheim US
Research & Development
Digital solutions save lives
Digital solutions save lives
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
US FDA accepts supplemental New Drug Application for Jardiance® (empagliflozin) for adults with heart failure with reduced ejection fraction
Results for Jardiance® (empaglifozin) | BI US
Read more about JARDIANCE, a significant reduction of risk for cardiovascular death or hospitalization for heart failure.
Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status
Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status
S&P Animal Health Partnering Oct 2023
Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
1885-1948: Innovative Beginnings | Boehringer Ingelheim US
Click here to read an in-depth history of Boehringer Ingelheim's formation, early days and what led us to being the global pharmaceutical company of today.
Boehringer Ingelheim hosts Governor Lamont press conference at our Apple Blossom learning center to support more on-site childcare options in Connecticut
Read about Connecticut Governor Ned Lamont and his administration’s visit to our U.S. headquarters in Ridgefield to tour our Apple Blossom Children’s Learning Center, to express the need for more childcare options for local communities and businesses.